Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VVN461 in Healthy Chinese Volunteers
NCT06906198Phase 1Completed
- Sponsor
- VivaVision Biotech
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VVN461 in post-operative ocular inflammation and non-infectious anterior uveitis (4 arms), sponsored by VivaVision Biotech. Primary endpoint: Safety outcome at Day 16. Started Mar 2023; status: completed.
02
Drugs
VVN461
03
Conditions
post-operative ocular inflammationnon-infectious anterior uveitis
Beyond the preview
Go deeper on NCT06906198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906198.